UK Type 1 diabetes patients miss out on glucose monitoring device, study says

636773636521167351diabetes sugar.jpg

09 Nov 2018 --- A flash glucose monitoring device made available on prescription across the UK last November is still not available to everyone who may need it, claims a study published in BMJ. According to the study’s findings, about 25 percent of clinical commissioning groups (CCG) do not recommend it to patients, thinking that it is too costly. 

According to the involved researchers, a quarter of CCGs have strict criteria for recommending the monitor. They focus on their short-term finances instead of realizing how much the monitor will benefit them if Type 1 diabetes patients do not often face complications, as they will be monitoring their sugar levels more efficiently. Many general practices ignore CCGs and recommend the device anyway as they believe it will help their patients.

“Unfortunately, the NHS does not have unlimited resources and ensuring patients get the best possible care against a backdrop of spiraling demands, competing priorities and increasing financial pressures is one of the biggest issues CCGs face,” says Julie Wood, Chief Executive of the NHS Clinical Commissioners. 

How it works
The flash glucose monitoring device, called Freestyle Libre and manufactured by Abbott, helps patients who suffer from Type 1 diabetes to monitor their sugar levels. According to Diabetes UK, a flash glucose monitor is a small sensor that you wear on your skin. It records your glucose (sugar) levels continuously throughout the day and you can access them by scanning the sensor whenever you want to. 

The sensor doesn’t actually measure your blood sugar level, it measures the amount of glucose in the fluid that surrounds your body cells. There is a sensor that sits just underneath your skin and measures your sugar levels. Then you swipe a reader over the sensor to get both your sugar level and the trend of your levels. 

The issue
There are 3.7 million people in the UK that suffer from diabetes and 400.000 of those are suffering from diabetes Type 1. Abbott’s Freestyle Libre is the sole glucose measuring device currently available in the UK and even Prime Minister Theresa May – who uses the device herself – told parliament that it is available through the NHS. 

However, some CCGs around the country do not actively recommend the device to patients, meaning people suffering from Type 1 diabetes either consider moving to a different general practice who can prescribe it without complications or fund it themselves, says Emma Wilmot, a Consultant Diabetologist. 

The sensor that goes under the patient's skin needs to be replaced every two weeks and that is a financial strain on people who use the Freestyle Libre without the NHS’s support.

Abbott, the company behind Freestyle Libre, shared an official statement with NutritionInsight when inquired on its stance on the matter.

“Our goal is to deliver NHS reimbursement of Abbott’s FreeStyle Libre system so that insulin-using people with diabetes can access this life-changing technology. Thanks in part to the tireless support of the diabetes community, including healthcare practitioners across the country, the first year since achieving NHS reimbursement has gone a long way in delivering this. More than 75 percent of local health economies now make FreeStyle Libre available in their area and we continue to work towards increasing access for insulin-using people with diabetes.”

Official prescribing data suggests that only two percent of patients with Type 1 diabetes in England are getting FreeStyle Libre on GP prescription, compared to 11 percent in Scotland, 16 percent in Wales, and 35 percent in Northern Ireland. The data was collated by diabetes campaigner Nick Cahm. 

As of July 2018, general practice prescribing data showed that only two out of 195 CCGs in England had prescribed Freestyle Libre to more than 20 percent of patients with Type 1 diabetes.

By Kristiana Lalou

To contact our editorial team please email us at editorial@cnsmedia.com

RELATED ARTICLES
Homepicture

Healthier indulgence: Beneo to showcase toffees with isomaltulose

25 Jan 2019 At this year’s ISM trade fair in Cologne, ...

Homepicture

“Landmark day”: GSK and Pfizer to form new Consumer Healthcare Joint Venture

19 Dec 2018 Pharma heavyweights GlaxoSmithKline plc (GSK) ...

Homepicture

Fermented horizons: NextFerm highlights yeast-derived astaxanthin

11 Dec 2018 NextFerm Technologies (Nextferm) is an Israeli ...